Clinical trials: Ischemic Symptoms
Carotid Artery Stenosis
Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum…
- Trial name
- NCT01654666
- Testing
- Remote ischemic preconditioning, Carotid Artery Stenting
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Ji Xunming
Obesity, Weight Loss
Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)
Although coronary heart disease (CHD) treatment guidelines recognize obesity as a major modifiable risk factor,2 nearly half of all CHD patients are obese and the current standard of care fails to implement evidence-based obesity…
- Conditions
- Obesity, Weight Loss, CHD - Coronary Heart Disease
- Trial name
- TOPCARE (NCT03423238)
- Testing
- Exercise, Health Education, Exercise Compliance
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Pelvic Pain
Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment
Our hypothesis is that with comparison of effectiveness of two most common techniques of treatment for myofascial pain syndrome (injection of local anesthesia and ischemic compression) we could choice the most adequate to treat…
- Trial name
- NCT00628355
- Testing
- lidocaine, Ischemic compression
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Cardiovascular Diseases, Myocardial Infarction
Subclinical Cardiovascular Disease in Psoriatic Disease
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
- Trial name
- NCT03228017
- Testing
- Aspirin and/or Atorvastatin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Coronary Artery Disease, Acute Coronary Syndrome
Tailored Antiplatelet Therapy Following PCI
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation.
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
- Trial name
- TAILOR-PCI (NCT01742117)
- Testing
- Clopidogrel, Ticagrelor
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 5,276 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Myocardial Infarction, Heart Failure
The Improving ATTENDance to Cardiac Rehabilitation Trial
The benefits of cardiac rehabilitation are well known. However, despite center based cardiac rehabilitation (CBCR) representing guideline-based care for patients with cardiovascular disease, most patients do not complete the…
- Conditions
- Myocardial Infarction, Heart Failure, Heart Valve Diseases, Cardiac Event
- Trial name
- iATTEND (NCT03646760)
- Testing
- HYCR, CBCR
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- Henry Ford Health System
Chronic Angina
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
According to the American Heart Association (AHA) 2011 update of heart disease and stroke statistics, more than 9 million adult patients in the United States (US) have angina.
- Trial name
- NCT00644332
- Testing
- Ranolazine
- Where
- 29 sites in United States
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Infarction
A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction
The purpose of this study is to evaluate whether the mobile-phone based patient support has an impact on the adherence and persistence of ticagrelor treatment or on lifestyle changes that will have a positive impact on the…
- Trial name
- SUPPORT (NCT01874262)
- Testing
- Mobile-phone based patient support, e-diary
- Where
- 13 sites in Sweden
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Ischemia
Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in…
- Trial name
- ambrisentan (NCT01072669)
- Testing
- ambrisentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soumya Chatterjee
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Stable Angina, Metabolic Syndrome
Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.
- Trial name
- IRMA (NCT02252406)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Florida
Transient Ischemic Attack, Stroke
Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
This program will seek to implement a quality improvement program to improve the care of Veterans with TIA or minor stroke at 6 Veteran Health Administration Hospitals.
- Trial name
- PREVENT (NCT02769338)
- Testing
- Quality Improvement Program
- Where
- United States
- Volunteers
- 2,292 people
- Sponsor
- VA Office of Research and Development
Cardiac Arrest
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial
Cardiac arrest is a sudden, unexpected loss of heart function. Therapeutic hypothermia, in which the body's temperature is lowered and maintained several degrees below normal for a period of time, has been used to successfully…
- Trial name
- THAPCA-IH (NCT00880087)
- Testing
- Therapeutic Hypothermia, Therapeutic Normothermia
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- University of Michigan
Myocardiopathies, Ischemia, Myocardial
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
- Conditions
- Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac
- Trial name
- EMMA (NCT00376532)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA